This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar - Takeaways - MDSpire

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

  • May 5, 2026

Share

  • 1

    The EU has approved the first pertuzumab biosimilar, POHERDY, for HER2-positive breast cancer, expanding treatment options in Europe.

  • 2

    POHERDY's approval is based on comprehensive data demonstrating high similarity to Roche's PERJETA, including efficacy and safety.

  • 3

    Genexine's GX-BP1 shows strong preclinical activity in resistant cancer models, achieving up to 96% tumor growth inhibition in combination therapies.

  • 4

    NICE has recommended rozanolixizumab as the first treatment for uncontrolled generalized myasthenia gravis in adults, available through interim funding.

  • 5

    Ecolab has opened a Bioprocessing Applications Lab in Korea to support biopharmaceutical manufacturers in optimizing purification workflows.

Original Source(s)

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

  • May 5, 2026

Related Content

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...

Early-Onset ICI-Related Myocarditis Linked to Increased Mortality

Early-onset of immune checkpoint inhibitor (ICI)-related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Assoc...